Drug Type Bispecific antibody |
Synonyms CYT-106 |
Target |
Mechanism CD38 modulators(Lymphocyte differentiation antigen CD38 modulators), NKp46 agonists(Natural cytotoxicity triggering receptor 1 agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Preclinical | US | 08 May 2020 | |
Multiple Myeloma | Preclinical | US | Cytovia Therapeutics, Inc.Startup | 08 May 2020 |
Multiple Myeloma | Preclinical | FR | 08 May 2020 |